Nurse Pract. 2023 Jun 1;48(6):36-47. doi: 10.1097/01.NPR.0000000000000059.
Effective management of dyslipidemia is of paramount importance to prevent cardiovascular (CV) complications. Using current clinical practice guidelines is recommended to correct lipid levels and prevent further pathologic processes. This article presents an overview of treatment options for patients with dyslipidemia and CV disease, with a special focus on the following drug classes: HMG-CoA reductase inhibitors (also called statins), cholesterol absorption inhibitors (ezetimibe), bile acid sequestrants, fibrates, icosapent ethyl, and PCSK9 inhibitors.
有效管理血脂异常对于预防心血管（CV）并发症至关重要。建议使用当前的临床实践指南来纠正血脂水平并防止进一步的病理过程。本文概述了血脂异常和 CV 疾病患者的治疗选择，特别关注以下药物类别：HMG-CoA 还原酶抑制剂（也称为他汀类药物）、胆固醇吸收抑制剂（依折麦布）、胆汁酸螯合剂、贝特类药物、icosapent ethyl 和 PCSK9 抑制剂。
